A Real-World Comparison of Drug Trough Levels between Patients Experiencing a Secondary Nonimmune Loss of Response and Those Maintaining a Response to Infliximab on Long-Term Maintenance Therapy for Inflammatory Bowel Disease
Our results did not demonstrate lower IFX levels among patients experiencing secondary nonimmune LOR on long-term therapy. Our results do not redefine the therapeutic IFX goal levels for those patients on long-term therapy and suggest that underdosing of IFX is not the cause of secondary LOR.
Authors
- Nina Kohn (ORCID: https://orcid.org/0000-0001-7979-2693)
- Arun Swaminath (ORCID: https://orcid.org/0000-0003-3495-012X)
- Jeremy Polman (ORCID: https://orcid.org/0000-0001-5222-2084)
- Keith Sultan (ORCID: https://orcid.org/0000-0002-7619-2024)
- Michael Färber
- Vincent Chua
Institutions
- Northwell Health (US)
- North Shore University Hospital (US)
- Lenox Hill Hospital (US)
- New York Institute of Technology (US)
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1159/000541377
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Northwell Health